Tower Research Capital (TRC)’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,481
| Closed | -$4K | – | 6666 |
|
|
2023
Q1 | $4K | Sell |
1,481
-5,208
| -78% | -$19.8K | ﹤0.01% | 5158 |
|
|
2022
Q4 | $27K | Buy |
6,689
+6,313
| +1,679% | +$38.6K | ﹤0.01% | 2866 |
|
|
2022
Q3 | $3K | Sell |
376
-54
| -13% | -$657 | ﹤0.01% | 5493 |
|
|
2022
Q2 | $5K | Buy |
430
+325
| +310% | +$3.05K | ﹤0.01% | 5151 |
|
|
2022
Q1 | $2K | Buy |
+105
| New | +$3.37K | ﹤0.01% | 5703 |
|
|
2021
Q4 | – | Sell |
-166
| Closed | -$11K | – | 6885 |
|
|
2021
Q3 | $11K | Buy |
+166
| New | +$11.9K | ﹤0.01% | 4286 |
|
|
2021
Q2 | – | Sell |
-906
| Closed | -$59K | – | 6086 |
|
|
2021
Q1 | $59K | Buy |
906
+25
| +3% | +$1.9K | ﹤0.01% | 2987 |
|
|
2020
Q4 | $51K | Buy |
+881
| New | +$51.3K | ﹤0.01% | 3117 |
|
|
2019
Q4 | – | Sell |
-63
| Closed | -$8K | – | 4653 |
|
|
2019
Q3 | $8K | Buy |
63
+19
| +43% | +$3.83K | ﹤0.01% | 3105 |
|
|
2019
Q2 | $13K | Buy |
+44
| New | +$18.4K | ﹤0.01% | 2430 |
|
|
2019
Q1 | – | Sell |
-89
| Closed | -$40K | – | 4488 |
|
|
2018
Q4 | $40K | Buy |
89
+78
| +709% | +$48.3K | ﹤0.01% | 1440 |
|
|
2018
Q3 | $10K | Buy |
+11
| New | +$7.26K | ﹤0.01% | 2792 |
|
|
2017
Q2 | – | Sell |
-3
| Closed | -$4K | – | 3663 |
|
|
2017
Q1 | $4K | Buy |
+3
| New | +$1.44K | ﹤0.01% | 2379 |
|
|
2016
Q4 | – | Sell |
-2
| Closed | -$1K | – | 4571 |
|
|
2016
Q3 | $1K | Sell |
2
-1
| -33% | -$447 | ﹤0.01% | 3420 |
|
|
2016
Q2 | $2K | Buy |
3
+2
| +200% | +$1.01K | ﹤0.01% | 4004 |
|
|
2016
Q1 | $1K | Sell |
1
-1
| -50% | -$559 | ﹤0.01% | 3855 |
|
|
2015
Q4 | $1K | Hold |
2
| – | – | ﹤0.01% | 4219 |
|
|
2015
Q3 | $3K | Buy |
+2
| New | +$3.09K | ﹤0.01% | 3200 |
|
Tower Research Capital (TRC)'s HTGM Position: Q2 2023 in Review
Tower Research Capital (TRC) sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 1,481 shares — an estimated $4K sold.
Tower Research Capital (TRC) first reported a position in HTGM in Q3 2015 and held it in 18 quarters. The position peaked at $59K in Q1 2021. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.
- Tower Research Capital (TRC) reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,481 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $4K.
- Tower Research Capital (TRC) first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2015 and held it in 18 quarters.
- Tower Research Capital (TRC)'s HTG Molecular Diagnostics, Inc. Common Stock position peaked at $59K in Q1 2021.
- 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.